Adjuvant nivolumab and relatlimab in stage III/IV melanoma: the randomized phase 3 RELATIVITY-098 trial.
Sign Up to like & getrecommendations! Published in 2025 at "Nature medicine"
DOI: 10.1038/s41591-025-04032-8
Abstract: Based on RELATIVITY-047, nivolumab plus relatlimab is approved for advanced melanoma. Here, to address a current unmet need for more efficacious adjuvant regimens for completely resected melanoma, the phase 3, double-blind RELATIVITY-098 trial compared adjuvant… read more here.
Keywords: stage iii; relativity 098; plus relatlimab; nivolumab ... See more keywords